BioMarin Pharmaceutical Inc. Reports Strong Second‑Quarter 2026 Results

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) released its financial and operating results for the quarter ended June 30 2026 on August 6, 2026. The company highlighted a 20 % year‑over‑year increase in total revenues, reaching $990 million, and announced a revised full‑year 2026 revenue outlook of at least $1 billion for its flagship product VOXZOGO®.

Key Financial Highlights

  • Total Revenues: $990 million (↑ 20 % YoY)
  • Guidance for Full‑Year 2026: Revenue ≥ $1 billion for VOXZOGO®
  • Non‑GAAP Diluted EPS: Expected to accrete in line with accelerated revenue growth and operating margin expansion
  • Operating Cash Flow: Projected to continue improving through the mid‑2030s

Product and Portfolio Developments

  • GALAFOLD® and POMBILITI® + OPFOLDA®: The addition of these products and the integration of Amicus are projected to accelerate revenue growth and improve operating metrics.
  • VOXZOGO®: Strong global demand has prompted the company to raise full‑year revenue guidance for this indication.

Strategic Operations

President and CEO Alexander Hardy noted that BioMarin has “executed strongly across our portfolio while rapidly integrating Amicus into BioMarin’s operations and advancing plans to accelerate growth for GALAFOLD and POMBILITI + OPFOLDA.” The company’s focus on expanding the benefits of these medicines to more patients worldwide is expected to drive continued growth.

Market Context

  • Closing Share Price (2026‑08‑04): $59.91
  • 52‑Week Range: $49.26 (low) – $66.28 (high)
  • Market Capitalization: $11.72 billion
  • P/E Ratio: 43.06

BioMarin’s performance reflects its ongoing commitment to developing therapeutic enzymes for lysosomal storage diseases and serious burns, as well as analytical and diagnostic products through its subsidiaries. The company’s recent earnings announcement and guidance upgrades reinforce its position as a leading biotechnology firm listed on the Nasdaq exchange.